ADUS Stock Analysis: Addus HomeCare | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 1.973m USD | 12M Return: -3.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.0M
EPS Trend: 99.1%
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Addus HomeCare Corporation (NASDAQ: ADUS) is a U.S.-based provider of in-home care services for elderly, chronically ill, and disabled individuals, as well as those at risk of hospitalization or institutionalization. Founded in 1979 and headquartered in Frisco, Texas, the company operates through three business segments: Personal Care, Hospice, and Home Health.
The Personal Care segment, which provides non-medical assistance with activities of daily living such as bathing, grooming, meal preparation, and transportation, represents the companys core offering. The Hospice segment delivers palliative nursing, social work, and bereavement counseling for terminally ill patients and their families, while the Home Health segment provides skilled nursing and physical, occupational, and speech therapy services for patients recovering from illness or hospitalization.
Addus serves a diverse payor mix that includes federal, state, and local government agencies, managed care organizations, commercial insurers, and private individuals. The companys heavy reliance on government payors - particularly Medicaid, which is the dominant funding source for personal care services in the U.S. - makes it sensitive to Medicaid reimbursement policy and rate-setting decisions. Demand is supported by long-term demographic tailwinds from the aging U.S. population and a broader preference for lower-cost in-home care over institutional settings.
- State Medicaid budget pressure threatens personal care margins
- Hospice segment growth accelerates post-Gentiva acquisition
- Caregiver wage inflation and staffing shortages squeeze operating margins
| Net Income: 99.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.17 > 1.0 |
| NWC/Revenue: 8.52% < 20% (prev 9.07%; Δ -0.55% < -1%) |
| CFO/TA 0.10 > 3% & CFO 144.9m > Net Income 99.8m |
| Net Debt (83.1m) to EBITDA (161.1m): 0.52 < 3 |
| Current Ratio: 1.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.5m) vs 12m ago 0.47% < -2% |
| Gross Margin: 32.45% > 18% (prev 32.56%; Δ -0.11% > 0.5%) |
| Asset Turnover: 101.9% > 50% (prev 86.07%; Δ 15.81% > 0%) |
| Interest Coverage Ratio: 12.31 > 6 (EBIT TTM 144.6m / Interest Expense TTM 11.7m) |
| A: 0.09 (Total Current Assets 272.9m - Total Current Liabilities 149.5m) / Total Assets 1.44b |
| B: 0.35 (Retained Earnings 497.4m / Total Assets 1.44b) |
| C: 0.10 (EBIT TTM 144.6m / Avg Total Assets 1.42b) |
| D: 3.49 (Book Value of Equity 1.12b / Total Liabilities 319.5m) |
| Altman-Z'' = 6.04 = AAA |
| DSRI: 0.88 (Receivables 148.6m/141.5m, Revenue 1.45b/1.21b) |
| GMI: 1.00 (GM 32.56% / 32.45%) |
| AQI: 1.00 (AQ_t 0.76 / AQ_t-1 0.77) |
| SGI: 1.20 (Revenue 1.45b / 1.21b) |
| TATA: -0.03 (NI 99.8m - CFO 144.9m) / TA 1.44b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 108.21 with a total of 207,607 shares traded. Over the past week, the price has changed by +2.89%, over one month by +16.14%, over three months by +17.35% and over the past year by -3.56%.
Current recommended Stop Loss: 101.70 (which is 6% or 2.3 ATR below the current price).
Addus HomeCare has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy ADUS.
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 132.7 | 22.6% |
P/E Trailing = 19.5074
P/E Forward = 15.1515
P/S = 1.3625
P/B = 1.7587
P/EG = 1.0103
Revenue TTM = 1.45b USD
EBIT TTM = 144.6m USD
EBITDA TTM = 161.1m USD
Long Term Debt = 91.3m USD (from longTermDebt, last quarter)
Short Term Debt = 13.1m USD (from shortTermDebt, last quarter)
Debt = 186.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 47.5m
Net Debt = 83.1m USD (calculated: Debt 186.2m - CCE 103.1m)
Enterprise Value = 2.06b USD (1.97b + Debt 186.2m - CCE 103.1m)
Interest Coverage Ratio = 12.31 (Ebit TTM 144.6m / Interest Expense TTM 11.7m)
EV/FCF = 14.97x (Enterprise Value 2.06b / FCF TTM 137.4m)
FCF Yield = 6.68% (FCF TTM 137.4m / Enterprise Value 2.06b)
FCF Margin = 9.48% (FCF TTM 137.4m / Revenue TTM 1.45b)
Net Margin = 6.89% (Net Income TTM 99.8m / Revenue TTM 1.45b)
Gross Margin = 32.45% ((Revenue TTM 1.45b - Cost of Revenue TTM 978.4m) / Revenue TTM)
Gross Margin QoQ = 31.87% (prev 33.13%)
Tobins Q-Ratio = 1.43 (Enterprise Value 2.06b / Total Assets 1.44b)
Interest Expense / Debt = 6.31% (Interest Expense 11.7m / Debt 186.2m)
Taxrate = 24.93% (33.1m / 132.9m)
NOPAT = 108.6m (EBIT 144.6m * (1 - 24.93%))
Current Ratio = 1.83 (Total Current Assets 272.9m / Total Current Liabilities 149.5m)
Debt / Equity = 0.17 (Debt 186.2m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = 0.52 (Net Debt 83.1m / EBITDA 161.1m)
Debt / FCF = 0.61 (Net Debt 83.1m / FCF TTM 137.4m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.02% (Net Income 99.8m / Total Assets 1.44b)
RoE = 9.34% (Net Income TTM 99.8m / Total Stockholder Equity 1.07b)
RoCE = 12.47% (EBIT 144.6m / Capital Employed (Equity 1.07b + L.T.Debt 91.3m))
RoIC = 8.85% (NOPAT 108.6m / Invested Capital 1.23b)
WACC = 6.88% (E(1.97b)/V(2.16b) * Re(7.08%) + D(186.2m)/V(2.16b) * Rd(6.31%) * (1-Tc(0.25)))
Discount Rate = 7.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 5.73%
[DCF] Terminal Value 77.97% ; FCFF base≈118.5m ; Y1≈135.8m ; Y5≈199.9m
[DCF] Fair Price = 156.7 (EV 3.01b - Net Debt 83.1m = Equity 2.92b / Shares 18.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.08 | EPS CAGR: 16.27% | SUE: -0.24 | # QB: 0
Revenue Correlation: 98.47 | Revenue CAGR: 14.59% | SUE: -0.83 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.69 | Chg30d=+0.09% | Revisions=-15% | Analysts=14
EPS next Quarter (2026-09-30): EPS=1.76 | Chg30d=+0.37% | Revisions=+27% | Analysts=14
EPS current Year (2026-12-31): EPS=6.99 | Chg30d=+1.39% | Revisions=+69% | GrowthEPS=+12.2% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=7.47 | Chg30d=+0.40% | Revisions=+0% | GrowthEPS=+6.9% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +26% (up=30, down=17)